Landos Biopharma

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients.

AbbVie

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP).

AbbVie Completes Acquisition of Landos Biopharma

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milest.

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP

MILWAUKEE , April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

NEW YORK , March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Landos Biopharma, Inc. (NASDAQ: LABP), relating to its proposed sale to AbbVie, Inc. Under the terms of the agreement, LABP shareholders are expected to receive $20.42 in cash plus one non-tradable CVR worth up to $11.14 per share they own.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABP

Landos Biopharma (NASDAQ: LABP ) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). AbbVie is acquiring Landos Biopharma for $20.42 per share in cash.

Why Is Landos Biopharma (LABP) Stock Up 168% Today?

MILWAUKEE , March 25, 2024 /PRNewswire/ -- Ademi LLP is investigating Landos (NASDAQ: LABP) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Landos Biopharma, Inc. (NASDAQ: LABP) to AbbVie Inc. is fair to Landos shareholders. Under the terms of the proposed transaction, AbbVie would acquire Landos for $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone. Halper Sadeh encourages Land.

LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders

AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.

AbbVie to buy Landos to expand pipeline of immunity-related illnesses

Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis  Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023. “We were focused in 2023 on advancing the NX-13 clinical program and establishing Landos as a leader in targeting immunometabolic pathways and developing novel and first-in-class, oral therapies for autoimmune diseases,” said Gregory Oakes, President and CEO of Landos.

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation

NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with  Top-line Results Planned for Q4 2024

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.

Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting

Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. “We continued to advance and execute the NX-13 Phase 2 clinical program (NEXUS) during the second quarter.

Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY.

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee.

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time today, May 25, 2023.

Landos Biopharma Announces 1-for-10 Reverse Stock Split

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. “We continue to execute on a focused strategy for the NX-13 program to maximize value for our shareholders,” said Gregory Oakes, President and CEO of Landos.

UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

Transaction Solidifies Company's Near-Term Strategic Focus on Advancing Clinical Development of NX-13

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos' Founder

Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023 Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn's and Colitis Organization

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis

News for Landos Biopharma Stock (LABP)